Publications by authors named "Stephanie Cardarella"

Claim this Profile
F
Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.
Jessica J Lin, Stephanie Cardarella, Christine A Lydon, Suzanne E Dahlberg, David M Jackman

J Thorac Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.
Mizuki Nishino, Stephanie Cardarella, Suzanne E Dahlberg, Tetsuro Araki, Christine Lydon

Eur J Radiol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer.
Dorothy Romanus, Stephanie Cardarella, David Cutler, Mary Beth Landrum, Neal I Lindeman

J Thorac Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.
Mizuki Nishino, Suzanne E Dahlberg, Stephanie Cardarella, David M Jackman, Michael S Rabin

Cancer· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of genomic changes on treatment of lung cancer.
Stephanie Cardarella, Bruce E Johnson

Am J Respir Crit Care Med· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.
Mizuki Nishino, Suzanne E Dahlberg, Stephanie Cardarella, David M Jackman, Michael S Rabin

J Thorac Oncol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
Stephanie Cardarella, Atsuko Ogino, Mizuki Nishino, Mohit Butaney, Jeanne Shen

Clin Cancer Res· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.
Mizuki Nishino, Stephanie Cardarella, David M Jackman, Nikhil H Ramaiya, Michael S Rabin

AJR Am J Roentgenol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of EGFR kinase inhibitors: not always greater than the sum of its parts.
Stephanie Cardarella, Bruce E Johnson

J Natl Cancer Inst· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.
Mizuki Nishino, Stephanie Cardarella, Suzanne E Dahlberg, David M Jackman, Nikhil H Ramaiya

Lung Cancer· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The introduction of systematic genomic testing for patients with non-small-cell lung cancer.
Stephanie Cardarella, Taylor M Ortiz, Victoria A Joshi, Mohit Butaney, David M Jackman

J Thorac Oncol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis